tradingview.comOct 30

Maxim Group initiates coverage of Nasus Pharma at Buy, sets price target at $7

Maxim Group initiated coverage of Nasus Pharma with a Buy rating and a $7 price target, implying 119.4% upside from the Oct 29 close of $3.19.

Original reporting

tradingview.com

Published Oct 30, 2026, 1:31 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 30, 2026, 1:37 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Maxim Group initiates coverage of Nasus Pharma at Buy, sets price target at $7 — source image — Source · tradingview.com

Decision brief

The 30-second read

Low

Why it matters

A new buy rating with a high target can attract short‑term buying pressure.

Market read

The article provides a fresh analyst rating that could influence trading decisions for the stock.

What to watch

Potential regulatory or clinical trial risks that could offset the rating boost.

Relevance 5/10Novelty 6/10Timing: today

Background

Analyst coverage initiations are common triggers for micro‑cap price moves.

Market effects

Sector

May lift sentiment in the small‑cap biotech sector.

Regional

Limited to markets where the stock trades.

Global

Low, confined to niche biotech investors.

Counterpoint

What could challenge this read

The price target may be overly optimistic given limited data on the company's pipeline.

Key entities

company
Nasus Pharma
Biotech firm receiving new analyst coverage.
analyst_firm
Maxim Group
Research house that initiated coverage.

Read at source ← All news

$NSRXMedAI 8/10

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Nasus Pharma (NYSE: NSRX) has enrolled and dosed the first patient in a Phase 1 trial for NS003, its intranasal ondansetron formulation. Pre-clinical studies showed NS003's PK profile was comparable to IV ondansetron, with a favorable safety profile. The company aims to announce topline PK data before year-end and initiate a pivotal NS002 study for anaphylaxis in Q4. Ondansetron is widely used for chemotherapy-induced nausea and vomiting, with peak sales exceeding $1.5 billion in 2023.

globenewswire.comSep 29

$TYRAHighAI 8/10

Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains

Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.

rttnews.comSep 14

$NSRXMed

Nasus Pharma Ltd (NSRX): Financial results for H1 2026

Nasus Pharma Ltd (NSRX) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, August

SEC EDGAR 6-KAug 17

$NVDAMed

Who is Colette Kress? All about Nvidia’s new interim CEO replacing Jensen Huang

Nvidia has appointed Colette Kress, its CFO, as interim CEO following Jensen Huang's resignation. Kress will retain her CFO role while leading the company. She has a long career in tech finance, including roles at Microsoft and Cisco. Nvidia's board is searching for a permanent CEO. (NVDA)

digit.inNov 12

$NVDAHigh

International Business: Nvidia CEO Jensen Huang steps down in big blow to AI boom

Nvidia CEO Jensen Huang is stepping down, with CFO Colette Kress taking over as interim CEO. Huang, Nvidia's co-founder and fourth-largest investor, will also exit the board. Nvidia shares fell over 10% in premarket trading. The company faces uncertainty as Huang was a key figure in its AI success. Michael Feldman of ClearBridge Investments noted concerns about execution risks without Huang's leadership.

gdnonline.comNov 12